Matinas BioPharma Holdings, Inc. Announces Executive Appointments
October 15, 2018 at 08:01 am EDT
Share
Matinas BioPharma Holdings, Inc. announced that it has appointed industry and drug development veteran Theresa Matkovits, Ph.D. as Chief Development Officer. The Company also announced that it has strengthened its manufacturing, supply chain and clinical development teams with the appointments of Frank Calamusa, CSCP and Jenel Cobb, Ph.D., PMP. The company further bolstered its manufacturing and clinical development teams with the appointments of Frank Calamusa, CSCP as Executive Director, Head of Manufacturing and Supply Chain and Jenel Cobb, Ph.D., PMP as Director, Project Management. Matkovits joins in the company having most recently served as the Chief Operating Officer of ContraVir Pharmaceuticals where she was instrumental in the establishment and build-out of its global development organization with responsibility and oversight for Clinical Development, Regulatory, Manufacturing, Quality, and Project Management functions, including the leadership of the global development efforts for the company’s antiviral portfolio. Mr. Calamusa is an established biotech CMC leader with 20+ years of experience in managing all aspects of early stage pharmaceutical development through product commercialization in both small molecule and biologics. He joins in the company having most recently served as Director, Pharmaceutical Development/Head of Manufacturing & Product Development at ContraVir Pharmaceuticals, where he was responsible for the development and implementation of clinical supply strategies for the antiviral portfolio ranging from pre-clinical to Phase 3. He also was responsible for leading and overseeing all company chemistry, manufacturing and controls (CMC) activities including manufacturing, quality, and regulatory submissions. Dr. Cobb is an accomplished project management professional with strong proven track record of managing global program teams to successfully deliver clinical, regulatory, manufacturing, and tox global program activities. She joins in the company having most recently served as Senior Project Manager at ContraVir Pharmaceuticals, where she was responsible for directly supporting the COO in the development of targeted antiviral therapies, in all phases of development, in the U.S., Europe and Asia. Over the course of her career, she has served as Senior Project Manager at LabCorp Clinical Trials, Associate Project Manager at Otsuka Pharmaceutical Development & Commercialization, and Project Manager at Niiki Pharma, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.